Wnt Pathway in Osteosarcoma, from Oncogenic to Therapeutic

被引:95
|
作者
Cai, Yu [1 ]
Cai, Tiange [2 ]
Chen, Yan [3 ]
机构
[1] Jinan Univ, Sch Pharm, Guangzhou 510632, Guangdong, Peoples R China
[2] Liaoning Univ, Sch Life Sci, Shenyang 110036, Peoples R China
[3] Univ Hlth Network, Ontario Canc Inst, Toronto, ON, Canada
关键词
Wnt; BETA-CATENIN; OSTEOSARCOMA; BETA-CATENIN; MONOCLONAL-ANTIBODY; INHIBITORY FACTOR-1; SIGNALING PATHWAY; PROTEIN-5; LRP5; CYCLIN D1; CELLS; EXPRESSION; PROLIFERATION; PROGRESSION;
D O I
10.1002/jcb.24708
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Osteosarcoma is the most common malignant bone tumor in children and adolescents. Although pathologic characteristics of this disease are clear and well established, much remains to be understood about this tumor, particularly at the molecular signaling level. Secreted signaling molecules of the Wnt family have been widely investigated and found to play a central role in controlling embryonic bone development, bone mass, and postnatal bone regeneration. A variety of studies also suggest that Wnt signaling pathway is closely associated with bone malignancies, including breast or prostate cancer induced bone metastasis, multiple myeloma, as well as osteosarcoma. Here, we provide an overview of the role of Wnt signaling pathway in osteosarcoma development and progression, highlighting the aberrant activation of Wnt pathway in this bone malignancy. We also discuss the potential therapeutic applications for the treatment of osteosarcoma targeting Wnt pathway. J. Cell. Biochem. 115: 625-631, 2014. (c) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:625 / 631
页数:7
相关论文
共 50 条
  • [41] WNT/β-CATENIN SIGNALING PATHWAY: A TARGET FOR NOVEL THERAPEUTIC APPROACHES IN MULTIPLE MYELOMA
    Gast, S-M
    Kim, Y.
    Schmidt-Wolf, I. G. H.
    DRUGS OF THE FUTURE, 2013, 38 (11) : 757 - 763
  • [42] Niclosamide and Pyrvinium Are Both Potential Therapeutics for Osteosarcoma, Inhibiting Wnt-Axin2-Snail Cascade
    Yi, Young
    Woo, Young Mi
    Hwang, Kyu Ho
    Kim, Hyun Sil
    Lee, Sang Hyeong
    CANCERS, 2021, 13 (18)
  • [43] Exploring the Wnt Pathway as a Therapeutic Target for Prostate Cancer
    Koushyar, Sarah
    Meniel, Valerie S.
    Phesse, Toby J.
    Pearson, Helen B.
    BIOMOLECULES, 2022, 12 (02)
  • [44] Wnt/β-catenin, an oncogenic pathway targeted by H-pylori in gastric carcinogenesis
    Song, Xiaowen
    Xin, Na
    Wang, Wei
    Zhao, Chenghai
    ONCOTARGET, 2015, 6 (34) : 35579 - 35588
  • [45] CEMIP Promotes Osteosarcoma Progression and Metastasis Through Activating Notch Signaling Pathway
    Cheng, Jun
    Zhang, Yan
    Wan, Rongjun
    Zhou, Jun
    Wu, Xin
    Fan, Qizhi
    He, Jingpeng
    Tan, Wei
    Deng, Youwen
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] The genetic basis for inactivation of Wnt pathway in human osteosarcoma
    Xiaoling Du
    Jilong Yang
    Da Yang
    Wei Tian
    Ze Zhu
    BMC Cancer, 14
  • [47] The WNT/ROR Pathway in Cancer: From Signaling to Therapeutic Intervention
    Menck, Kerstin
    Heinrichs, Saskia
    Baden, Cornelia
    Bleckmann, Annalen
    CELLS, 2021, 10 (01) : 1 - 32
  • [48] TIKI2 suppresses growth of osteosarcoma by targeting Wnt/β-catenin pathway
    Ruhui Li
    Jianguo Liu
    Hong Wu
    Lidi Liu
    Lijun Wang
    Shaokun Zhang
    Molecular and Cellular Biochemistry, 2014, 392 : 109 - 116
  • [49] Fibulin-4 is a novel Wnt/β-Catenin pathway activator in human osteosarcoma
    Li, Renzeng
    Wang, Limin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 474 (04) : 730 - 735
  • [50] Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?
    Ameline, Baptiste
    Kovac, Michal
    Nathrath, Michaela
    Barenboim, Maxim
    Witt, Olaf
    Krieg, Andreas H.
    Baumhoer, Daniel
    JOURNAL OF PATHOLOGY CLINICAL RESEARCH, 2021, 7 (02) : 165 - 172